Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Payables (2016 - 2025)

Apyx Medical's Payables history spans 16 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Payables rose 16.94% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, up 16.94%, while the annual FY2025 figure was $3.1 million, 16.94% up from the prior year.
  • Payables reached $3.1 million in Q4 2025 per APYX's latest filing, down from $3.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.2 million in Q3 2025 to a low of $1.9 million in Q1 2023.
  • Average Payables over 5 years is $2.5 million, with a median of $2.6 million recorded in 2022.
  • Peak YoY movement for Payables: surged 74.12% in 2021, then tumbled 32.0% in 2022.
  • A 5-year view of Payables shows it stood at $2.6 million in 2021, then increased by 1.44% to $2.7 million in 2022, then increased by 1.61% to $2.7 million in 2023, then dropped by 3.58% to $2.6 million in 2024, then grew by 16.94% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Payables are $3.1 million (Q4 2025), $3.2 million (Q3 2025), and $2.9 million (Q2 2025).